Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Συντάκτης(Asc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., Zavos C., Pyrrou N., & Tantsi N. (2013).  Helicobacter pylori infection and serum adiponectin.. Helicobacter. 18(4), 321-2.
Polyzos, S. A., Cundy T., & Mantzoros C. S. (2018).  Juvenile Paget disease.. Metabolism. 80, 15-26.
Polyzos, S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., & Kountouras J. (2014).  Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.. Arq Gastroenterol. 51(3), 261-8.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review.. Thyroid. 20(3), 265-71.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review.. Expert Rev Endocrinol Metab. 5(5), 673-679.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2015).  Leptin in nonalcoholic fatty liver disease: a narrative review.. Metabolism. 64(1), 60-78.
Polyzos, S. A., Kang E. Seok, Boutari C., Rhee E-J., & Mantzoros C. S. (2020).  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.. Metabolism. 154203.
Polyzos, S. A., Kechagias S., & Tsochatzis E. A. (2021).  Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.. Aliment Pharmacol Ther.
Polyzos, S. A., Kountouras J., & Zavos C. (2011).  Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas.. Int J Clin Pract. 65(3), 373-4.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., Kountouras J., Goulas A., Papakonstantinou E., & Papaioannidou P. (2020).  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.. Hepatobiliary Surg Nutr. 9(1), 73-76.
Polyzos, S. A., Mathew H., & Mantzoros C. S. (2015).  Irisin: A true, circulating hormone.. Metabolism. 64(12), 1611-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2012).  Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease.. Metabolism. 61(6), 755-8.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., & Margioris A. N. (2018).  Sarcopenic obesity.. Hormones (Athens). 17(3), 321-331.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Polyzos, S. A., Goulis D. G., Giouleme O., Germanidis G. S., & Goulas A. (2022).  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis. Current Medicinal Chemistry. 30,
Polyzos, S. A., Anastasilakis A. D., Makras P., & Terpos E. (2011).  Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.. Exp Clin Endocrinol Diabetes. 119(9), 519-24.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.